{"id":15156,"date":"2026-01-25T02:01:34","date_gmt":"2026-01-25T02:01:34","guid":{"rendered":"https:\/\/craighordlow.com\/?p=15156"},"modified":"2026-01-25T02:04:57","modified_gmt":"2026-01-25T02:04:57","slug":"age-related-macular-degeneration-amd","status":"publish","type":"post","link":"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/","title":{"rendered":"Age-Related Macular Degeneration (AMD)"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tCLICK HERE TO DOWNLOAD PDF<\/A>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\r\n\r\n\r\n \r\n \r\n Absence of Evidence: SkQ1 (Visomitin) for AMD<\/title>\r\n <link href=\"https:\/\/fonts.googleapis.com\/css2?family=Inter:wght@400;600;700;900&display=swap\" rel=\"stylesheet\">\r\n <link href=\"https:\/\/cdnjs.cloudflare.com\/ajax\/libs\/font-awesome\/6.0.0-beta3\/css\/all.min.css\" rel=\"stylesheet\">\r\n <style>\r\n * {\r\n margin: 0;\r\n padding: 0;\r\n box-sizing: border-box;\r\n }\r\n \r\n body {\r\n font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;\r\n background-color: #FFFFFF;\r\n color: #1a1a1a;\r\n line-height: 1.6;\r\n font-size: 20px;\r\n }\r\n \r\n .article-container {\r\n max-width: 900px;\r\n margin: 0 auto;\r\n padding: 40px 20px;\r\n }\r\n \r\n \/* Header *\/\r\n .article-header {\r\n text-align: center;\r\n margin-bottom: 60px;\r\n padding-bottom: 30px;\r\n border-bottom: 4px solid #003366;\r\n }\r\n \r\n h1 {\r\n font-size: 48px;\r\n font-weight: 900;\r\n color: #003366;\r\n margin-bottom: 20px;\r\n line-height: 1.2;\r\n }\r\n \r\n .subtitle {\r\n font-size: 24px;\r\n color: #CC3300;\r\n font-weight: 700;\r\n text-transform: uppercase;\r\n letter-spacing: 2px;\r\n }\r\n \r\n \/* Section Styling *\/\r\n .section {\r\n margin-bottom: 60px;\r\n }\r\n \r\n h2 {\r\n font-size: 36px;\r\n font-weight: 900;\r\n color: #003366;\r\n margin-bottom: 20px;\r\n padding-top: 20px;\r\n border-top: 2px solid #E0E0E0;\r\n }\r\n \r\n h3 {\r\n font-size: 28px;\r\n font-weight: 700;\r\n color: #003366;\r\n margin-bottom: 15px;\r\n margin-top: 30px;\r\n }\r\n \r\n p {\r\n font-size: 22px;\r\n line-height: 1.7;\r\n margin-bottom: 20px;\r\n color: #333;\r\n }\r\n \r\n .highlight {\r\n background-color: #FFF8E1;\r\n padding: 2px 6px;\r\n font-weight: 700;\r\n color: #000;\r\n }\r\n \r\n .text-red {\r\n color: #CC3300;\r\n font-weight: 700;\r\n }\r\n \r\n .text-green {\r\n color: #2E7D32;\r\n font-weight: 700;\r\n }\r\n \r\n \/* Info Boxes *\/\r\n .info-box {\r\n padding: 25px;\r\n margin: 30px 0;\r\n border-left: 8px solid #003366;\r\n background-color: #F9F9F9;\r\n }\r\n \r\n .info-box.warning {\r\n border-left-color: #CC3300;\r\n background-color: #FFF5F5;\r\n }\r\n \r\n .info-box.success {\r\n border-left-color: #2E7D32;\r\n background-color: #F0F9F0;\r\n }\r\n \r\n .info-box h3 {\r\n margin-top: 0;\r\n display: flex;\r\n align-items: center;\r\n gap: 12px;\r\n }\r\n \r\n .info-box p {\r\n margin-bottom: 0;\r\n }\r\n \r\n \/* Table Styling *\/\r\n table {\r\n width: 100%;\r\n border-collapse: collapse;\r\n margin: 30px 0;\r\n font-size: 20px;\r\n }\r\n \r\n th {\r\n background-color: #003366;\r\n color: #FFFFFF;\r\n padding: 20px;\r\n text-align: left;\r\n font-size: 24px;\r\n font-weight: 700;\r\n }\r\n \r\n td {\r\n padding: 18px 20px;\r\n border-bottom: 1px solid #E0E0E0;\r\n font-size: 22px;\r\n line-height: 1.5;\r\n }\r\n \r\n tr:nth-child(even ) {\r\n background-color: #F9F9F9;\r\n }\r\n \r\n .icon-check {\r\n color: #2E7D32;\r\n font-size: 24px;\r\n }\r\n \r\n .icon-cross {\r\n color: #CC3300;\r\n font-size: 24px;\r\n }\r\n \r\n \/* List Styling *\/\r\n ul {\r\n margin: 20px 0;\r\n padding-left: 0;\r\n list-style: none;\r\n }\r\n \r\n li {\r\n font-size: 22px;\r\n margin-bottom: 15px;\r\n padding-left: 40px;\r\n position: relative;\r\n line-height: 1.6;\r\n }\r\n \r\n li::before {\r\n content: \"\u2713\";\r\n position: absolute;\r\n left: 0;\r\n color: #2E7D32;\r\n font-weight: 900;\r\n font-size: 28px;\r\n }\r\n \r\n \/* Citation Styling *\/\r\n .citation {\r\n margin: 25px 0;\r\n padding: 20px;\r\n background-color: #F5F7FA;\r\n border-left: 4px solid #003366;\r\n }\r\n \r\n .citation-title {\r\n font-size: 22px;\r\n font-weight: 700;\r\n color: #003366;\r\n margin-bottom: 8px;\r\n }\r\n \r\n .citation-source {\r\n font-size: 18px;\r\n font-style: italic;\r\n color: #666;\r\n margin-bottom: 10px;\r\n }\r\n \r\n .citation-summary {\r\n font-size: 20px;\r\n color: #333;\r\n }\r\n \r\n \/* Link Placeholder *\/\r\n .link-placeholder {\r\n margin: 20px 0;\r\n padding: 20px;\r\n background-color: #E0E0E0;\r\n border: 3px dashed #666;\r\n text-align: center;\r\n font-size: 24px;\r\n font-weight: 700;\r\n color: #555;\r\n }\r\n \r\n \/* Responsive Design *\/\r\n @media (max-width: 768px) {\r\n h1 { font-size: 36px; }\r\n h2 { font-size: 28px; }\r\n h3 { font-size: 24px; }\r\n p, li, td { font-size: 20px; }\r\n th { font-size: 22px; }\r\n .article-container { padding: 20px 15px; }\r\n }\r\n \r\n @media (max-width: 480px) {\r\n h1 { font-size: 28px; }\r\n h2 { font-size: 24px; }\r\n h3 { font-size: 20px; }\r\n p, li, td { font-size: 18px; }\r\n }\r\n <\/style>\r\n<\/head>\r\n<body>\r\n <article class=\"article-container\">\r\n <!-- Header -->\r\n <header class=\"article-header\">\r\n <div class=\"subtitle\">A Critical Examination<\/div>\r\n <div id=\"ez-toc-container\" class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Absence_of_Evidence_SkQ1_Visomitin_for_AMD\" >Absence of Evidence: SkQ1 (Visomitin) for AMD<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Treatment_Gap_in_AMD\" >The Treatment Gap in AMD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Clinical_Reality_When_Standard_of_Care_Fails\" >The Clinical Reality: When Standard of Care Fails<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Current_Treatment_Outcomes\" >Current Treatment Outcomes<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Mitochondrial_Dysfunction_The_Root_Cause\" >Mitochondrial Dysfunction: The Root Cause<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Cascade\" >The Cascade:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#SkQ1_A_Mitochondria-Targeted_Antioxidant\" >SkQ1: A Mitochondria-Targeted Antioxidant<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Mechanism_of_Action\" >Mechanism of Action:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Preclinical_Evidence\" >Preclinical Evidence<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Why_No_Phase_3_Trials_The_Economic_Reality\" >Why No Phase 3 Trials? The Economic Reality<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Epistemological_Trap\" >The Epistemological Trap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#What_We_DO_Have\" >What We DO Have:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#SkQ1_Occupies_the_%22Absence_of_Evidence%22_Zone\" >SkQ1 Occupies the \"Absence of Evidence\" Zone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#When_Standard_of_Care_Fails_A_Patient_Case_Study\" >When Standard of Care Fails: A Patient Case Study<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Prognosis\" >The Prognosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_SkQ1_Result_35_Weeks\" >The SkQ1 Result (3.5 Weeks)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Sourcing_SkQ1_Visomitin\" >Sourcing SkQ1 (Visomitin)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Status_Not_in_US_Pharmacies\" >Status: Not in US Pharmacies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Where_to_Buy\" >Where to Buy<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#Key_Scientific_References\" >Key Scientific References<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#The_Path_Forward\" >The Path Forward<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#For_Patients\" >For Patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#For_Medicine\" >For Medicine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/craighordlow.com\/index.php\/2026\/01\/25\/age-related-macular-degeneration-amd\/#For_Science\" >For Science<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Absence_of_Evidence_SkQ1_Visomitin_for_AMD\"><\/span>Absence of Evidence: SkQ1 (Visomitin) for AMD<span class=\"ez-toc-section-end\"><\/span><\/h1>\r\n <p style=\"font-size: 20px; color: #666; margin-top: 20px;\">\"Absence of evidence is not evidence of absence.\" \u2014 Carl Sagan<\/p>\r\n <\/header>\r\n\r\n <!-- Section 1: The Gap -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"The_Treatment_Gap_in_AMD\"><\/span>The Treatment Gap in AMD<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n <p>Current standard of care for Age-Related Macular Degeneration (AMD) focuses exclusively on <strong>symptom management<\/strong> rather than addressing the underlying cause. This creates a significant gap in patient outcomes.<\/p>\r\n \r\n <table>\r\n <thead>\r\n <tr>\r\n <th>Feature<\/th>\r\n <th>Standard of Care<\/th>\r\n <th>The Gap<\/th>\r\n <th>SkQ1 Potential<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><strong>Targets Root Cause<\/strong><\/td>\r\n <td><i class=\"fas fa-times icon-cross\"><\/i> No<\/td>\r\n <td>Mitochondrial dysfunction ignored<\/td>\r\n <td><i class=\"fas fa-check icon-check\"><\/i> Yes<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Treats Dry AMD<\/strong><\/td>\r\n <td><i class=\"fas fa-times icon-cross\"><\/i> No effective treatment<\/td>\r\n <td>85-90% of patients left untreated<\/td>\r\n <td><i class=\"fas fa-check icon-check\"><\/i> Preclinical evidence<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Restores Function<\/strong><\/td>\r\n <td><i class=\"fas fa-times icon-cross\"><\/i> Slows decline only<\/td>\r\n <td>No reversal mechanism<\/td>\r\n <td><i class=\"fas fa-check icon-check\"><\/i> Normalizes VEGF\/PEDF<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Prevents Progression<\/strong><\/td>\r\n <td><i class=\"fas fa-minus\" style=\"color: #FF9800;\"><\/i> Limited<\/td>\r\n <td>63.3% still lose vision<\/td>\r\n <td><i class=\"fas fa-check icon-check\"><\/i> Prevents pathology<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/section>\r\n\r\n <!-- Section 2: Clinical Reality -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"The_Clinical_Reality_When_Standard_of_Care_Fails\"><\/span>The Clinical Reality: When Standard of Care Fails<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <div class=\"info-box warning\">\r\n <h3><span class=\"ez-toc-section\" id=\"Current_Treatment_Outcomes\"><\/span><i class=\"fas fa-exclamation-triangle\"><\/i> Current Treatment Outcomes<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p><strong class=\"text-red\">63.3% of eyes<\/strong> treated with anti-VEGF injections still lose \u226515 letters of vision over 2 years.<\/p>\r\n <p style=\"margin-top: 15px;\"><strong class=\"text-red\">11.7 hours per year<\/strong> average burden on patients and caregivers for clinic visits and injections.<\/p>\r\n <\/div>\r\n \r\n <p>Despite being the \"gold standard,\" anti-VEGF therapy:<\/p>\r\n <ul>\r\n <li>Does <strong>not<\/strong> address the root cause (mitochondrial oxidative stress)<\/li>\r\n <li>Requires invasive, repeated intravitreal injections<\/li>\r\n <li>Offers <strong>no solution<\/strong> for Dry AMD (85-90% of cases)<\/li>\r\n <li>Suppresses VEGF rather than restoring natural balance<\/li>\r\n <\/ul>\r\n <\/section>\r\n\r\n <!-- Section 3: The Root Cause -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"Mitochondrial_Dysfunction_The_Root_Cause\"><\/span>Mitochondrial Dysfunction: The Root Cause<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <p>The pathogenesis of AMD begins with <strong>mitochondrial oxidative stress<\/strong> in the Retinal Pigment Epithelium (RPE). This is not speculation\u2014it is established science.<\/p>\r\n \r\n <h3><span class=\"ez-toc-section\" id=\"The_Cascade\"><\/span>The Cascade:<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <ol style=\"list-style: decimal; padding-left: 40px;\">\r\n <li style=\"list-style: decimal;\"><strong>Mitochondrial ROS accumulation<\/strong> \u2192 Damages RPE cells<\/li>\r\n <li style=\"list-style: decimal;\"><strong>RPE dysfunction<\/strong> \u2192 Disrupts VEGF\/PEDF balance<\/li>\r\n <li style=\"list-style: decimal;\"><strong>VEGF overexpression<\/strong> \u2192 Neovascularization (Wet AMD)<\/li>\r\n <li style=\"list-style: decimal;\"><strong>Chronic inflammation<\/strong> \u2192 Drusen formation (Dry AMD)<\/li>\r\n <\/ol>\r\n \r\n <div class=\"info-box\">\r\n <p><strong>Key Insight:<\/strong> Current treatments target Step 3 (VEGF). SkQ1 targets <span class=\"text-green\">Step 1<\/span> (Mitochondrial ROS).<\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- Section 4: What is SkQ1? -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"SkQ1_A_Mitochondria-Targeted_Antioxidant\"><\/span>SkQ1: A Mitochondria-Targeted Antioxidant<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <p><strong>SkQ1 (Visomitin)<\/strong> is a rechargeable antioxidant that selectively accumulates in mitochondria at concentrations 1000x higher than in the cytoplasm.<\/p>\r\n \r\n <h3><span class=\"ez-toc-section\" id=\"Mechanism_of_Action\"><\/span>Mechanism of Action:<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <ul>\r\n <li><strong>Penetrates mitochondrial membrane<\/strong> via lipophilic cation structure<\/li>\r\n <li><strong>Neutralizes ROS<\/strong> at the source (Complex I\/III of electron transport chain)<\/li>\r\n <li><strong>Restores VEGF\/PEDF balance<\/strong> by reducing oxidative stress signals<\/li>\r\n <li><strong>Prevents RPE apoptosis<\/strong> and choroidal degradation<\/li>\r\n <\/ul>\r\n \r\n <div class=\"info-box success\">\r\n <h3><span class=\"ez-toc-section\" id=\"Preclinical_Evidence\"><\/span><i class=\"fas fa-microscope\"><\/i> Preclinical Evidence<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>In OXYS rats (a validated AMD model), SkQ1 eye drops:<\/p>\r\n <ul style=\"margin-top: 15px;\">\r\n <li><strong>Prevented<\/strong> pathological changes in RPE and choroid<\/li>\r\n <li><strong>Normalized<\/strong> VEGF and PEDF expression (not ablated)<\/li>\r\n <li><strong>Restored<\/strong> \u03b1B-crystallin levels (cellular protection)<\/li>\r\n <li><strong>Reversed<\/strong> early-stage retinopathy<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- Section 5: The Economic Barrier -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"Why_No_Phase_3_Trials_The_Economic_Reality\"><\/span>Why No Phase 3 Trials? The Economic Reality<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <p>The absence of large-scale clinical trials for SkQ1 is not a reflection of its scientific merit. It is a consequence of <strong>economic incentives<\/strong>.<\/p>\r\n \r\n <table>\r\n <thead>\r\n <tr>\r\n <th>Factor<\/th>\r\n <th>Reality<\/th>\r\n <\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><strong>Phase 3 Trial Cost<\/strong><\/td>\r\n <td>$50-100 million USD<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Patent Status<\/strong><\/td>\r\n <td><span class=\"text-red\">Expired<\/span> (no exclusivity)<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Market Size<\/strong><\/td>\r\n <td>Large, but <strong>no monopoly pricing<\/strong><\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>ROI for Pharma<\/strong><\/td>\r\n <td><span class=\"text-red\">Negative<\/span> (generics can copy immediately)<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n \r\n <div class=\"info-box warning\">\r\n <h3><span class=\"ez-toc-section\" id=\"The_Epistemological_Trap\"><\/span><i class=\"fas fa-balance-scale\"><\/i> The Epistemological Trap<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p><strong>The Fallacy:<\/strong> \"There are no Phase 3 trials, therefore SkQ1 does not work.\"<\/p>\r\n <p style=\"margin-top: 15px;\"><strong>The Reality:<\/strong> \"There are no Phase 3 trials because <span class=\"highlight\">the patent expired<\/span>, removing the financial incentive to fund them.\"<\/p>\r\n <\/div>\r\n \r\n <h3><span class=\"ez-toc-section\" id=\"What_We_DO_Have\"><\/span>What We DO Have:<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <ul>\r\n <li><strong>Valid Mechanism:<\/strong> Targets mitochondrial ROS directly<\/li>\r\n <li><strong>Animal Models:<\/strong> Prevents AMD-like pathology in OXYS rats<\/li>\r\n <li><strong>Safety Data:<\/strong> Phase 2 trials in Russia (dry eye syndrome)<\/li>\r\n <li><strong>Biological Plausibility:<\/strong> Peer-reviewed in <em>Antioxidants<\/em>, <em>PLoS One<\/em>, <em>Biochemistry<\/em><\/li>\r\n <\/ul>\r\n <\/section>\r\n\r\n <!-- Section 6: The Evidence Matrix -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"SkQ1_Occupies_the_%22Absence_of_Evidence%22_Zone\"><\/span>SkQ1 Occupies the \"Absence of Evidence\" Zone<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <p>This matrix illustrates why SkQ1 lacks clinical trials despite strong biological rationale:<\/p>\r\n \r\n <div style=\"text-align: center; margin: 40px 0;\">\r\n <svg width=\"700\" height=\"500\" viewBox=\"0 0 700 500\" style=\"max-width: 100%; height: auto;\">\r\n <!-- Axes -->\r\n <line x1=\"100\" y1=\"400\" x2=\"650\" y2=\"400\" stroke=\"#333\" stroke-width=\"3\"\/>\r\n <line x1=\"100\" y1=\"400\" x2=\"100\" y2=\"50\" stroke=\"#333\" stroke-width=\"3\"\/>\r\n \r\n <!-- Labels -->\r\n <text x=\"375\" y=\"450\" text-anchor=\"middle\" font-size=\"20\" font-weight=\"700\" fill=\"#003366\">Economic Incentive \u2192<\/text>\r\n <text x=\"40\" y=\"225\" text-anchor=\"middle\" font-size=\"20\" font-weight=\"700\" fill=\"#003366\" transform=\"rotate(-90 40 225)\">Efficacy\/Potential \u2192<\/text>\r\n \r\n <!-- Quadrant Labels -->\r\n <text x=\"200\" y=\"120\" text-anchor=\"middle\" font-size=\"18\" font-weight=\"700\" fill=\"#CC3300\">\"Absence of Evidence\"<\/text>\r\n <text x=\"200\" y=\"145\" text-anchor=\"middle\" font-size=\"16\" fill=\"#666\">(High Potential \/ Low Incentive)<\/text>\r\n \r\n <!-- SkQ1 Point -->\r\n <circle cx=\"180\" cy=\"180\" r=\"12\" fill=\"#CC3300\"\/>\r\n <text x=\"180\" y=\"210\" text-anchor=\"middle\" font-size=\"20\" font-weight=\"900\" fill=\"#CC3300\">SkQ1<\/text>\r\n \r\n <!-- Standard of Care Cloud -->\r\n <ellipse cx=\"480\" cy=\"280\" rx=\"120\" ry=\"80\" fill=\"#003366\" opacity=\"0.2\"\/>\r\n <text x=\"480\" y=\"285\" text-anchor=\"middle\" font-size=\"18\" font-weight=\"700\" fill=\"#003366\">Standard<\/text>\r\n <text x=\"480\" y=\"305\" text-anchor=\"middle\" font-size=\"18\" font-weight=\"700\" fill=\"#003366\">of Care<\/text>\r\n \r\n <!-- Snake Oil Corner -->\r\n <text x=\"550\" y=\"120\" text-anchor=\"middle\" font-size=\"16\" fill=\"#999\">\"Snake Oil\"<\/text>\r\n <\/svg>\r\n <\/div>\r\n \r\n <p><strong>Key Observation:<\/strong> SkQ1 sits in the top-left quadrant\u2014high biological potential, but low commercial incentive. This is where <span class=\"highlight\">promising therapies go to die<\/span> in our current pharmaceutical system.<\/p>\r\n <\/section>\r\n\r\n <!-- Section 7: Patient Case Study -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"When_Standard_of_Care_Fails_A_Patient_Case_Study\"><\/span>When Standard of Care Fails: A Patient Case Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <div class=\"info-box warning\">\r\n <h3><span class=\"ez-toc-section\" id=\"The_Prognosis\"><\/span><i class=\"fas fa-user-md\"><\/i> The Prognosis<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>After exhausting standard treatments, my mother's ophthalmologists confirmed there was nothing more they could do. The prognosis was <strong>total blindness<\/strong>.<\/p>\r\n <\/div>\r\n \r\n <div class=\"info-box success\">\r\n <h3><span class=\"ez-toc-section\" id=\"The_SkQ1_Result_35_Weeks\"><\/span><i class=\"fas fa-eye\"><\/i> The SkQ1 Result (3.5 Weeks)<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>After starting Visomitin drops (SkQ1), her condition began reversing. <span class=\"highlight\">\"She is seeing things she could not see 4 weeks ago.\"<\/span><\/p>\r\n <\/div>\r\n \r\n <p><strong>Disclaimer:<\/strong> I am a molecular biologist with a background in cancer therapeutics (therapeutic apheresis), not an ophthalmologist. I am not providing medical advice. I am reporting a functional outcome in a case where standard care had failed.<\/p>\r\n <\/section>\r\n\r\n <!-- Section 8: Availability -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"Sourcing_SkQ1_Visomitin\"><\/span>Sourcing SkQ1 (Visomitin)<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <div class=\"info-box warning\">\r\n <h3><span class=\"ez-toc-section\" id=\"Status_Not_in_US_Pharmacies\"><\/span><i class=\"fas fa-exclamation-triangle\"><\/i> Status: Not in US Pharmacies<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>Visomitin is a Russian product. Financial sanctions and tariffs make it difficult to obtain through standard channels.<\/p>\r\n <\/div>\r\n \r\n <div class=\"info-box success\">\r\n <h3><span class=\"ez-toc-section\" id=\"Where_to_Buy\"><\/span><i class=\"fas fa-globe\"><\/i> Where to Buy<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>I have successfully ordered twice from <strong>RuPharma<\/strong> (International Pharmacy).<\/p>\r\n \r\n <div class=\"link-placeholder\">\r\n <a href=\"https:\/\/rupharma.com\/visomitin\/?aff=259\" =_blank target=\"_blank\" rel=\"noopener\">RUPharma's Visotimin page<\/a>\r\n <\/div>\r\n \r\n <p style=\"margin-top: 20px; font-size: 20px; font-style: italic; color: #666;\">\r\n <strong>Note:<\/strong> Payment often requires Bitcoin\/Crypto due to credit card restrictions on Russian vendors. I received a 10% discount using Bitcoin.\r\n <\/p>\r\n <\/div>\r\n \r\n <p><strong>Questions?<\/strong> Email me at: <a href=\"mailto:chordlow@gmail.com\" style=\"color: #003366; font-weight: 700;\">chordlow@gmail.com<\/a><\/p>\r\n <\/section>\r\n\r\n <!-- Section 9: References -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"Key_Scientific_References\"><\/span>Key Scientific References<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <div class=\"citation\">\r\n <div class=\"citation-title\">Mitochondria-targeted antioxidant SkQ1 prevents age-related macular degeneration-like pathology in OXYS rats<\/div>\r\n <div class=\"citation-source\">Muraleva NA, Kolosova NG, et al. <em>Antioxidants (Basel)<\/em>. 2019;8(6):177.<\/div>\r\n <div class=\"citation-summary\"><strong>Key Finding:<\/strong> SkQ1 drops prevented pathological changes in the RPE and choroid, confirming <span class=\"text-green\">mitochondrial ROS as a therapeutic target<\/span>.<\/div>\r\n <\/div>\r\n \r\n <div class=\"citation\">\r\n <div class=\"citation-title\">Suppression of AMD-Like Pathology by Mitochondria-Targeted Antioxidant SkQ1 Is Associated with a Decrease in the Accumulation of Amyloid Beta<\/div>\r\n <div class=\"citation-source\">Ioshchenko FW, Kolosova NG, et al. <em>Int J Mol Sci<\/em>. 2018.<\/div>\r\n <div class=\"citation-summary\"><strong>Key Finding:<\/strong> Demonstrated that SkQ1 <span class=\"text-green\">normalizes VEGF and PEDF expression<\/span>, restoring the natural balance rather than ablating it.<\/div>\r\n <\/div>\r\n \r\n <div class=\"citation\">\r\n <div class=\"citation-title\">An attempt to prevent senescence: a mitochondrial approach<\/div>\r\n <div class=\"citation-source\">Skulachev VP, et al. <em>Biochim Biophys Acta<\/em>. 2009;1787(5):437-461.<\/div>\r\n <div class=\"citation-summary\"><strong>Key Finding:<\/strong> The foundational paper establishing the mechanism of SkQ1 as a <span class=\"text-green\">rechargeable antioxidant<\/span> that accumulates in mitochondria.<\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- Section 10: Conclusion -->\r\n <section class=\"section\">\r\n <h2><span class=\"ez-toc-section\" id=\"The_Path_Forward\"><\/span>The Path Forward<span class=\"ez-toc-section-end\"><\/span><\/h2>\r\n \r\n <div class=\"info-box\" style=\"border-left-color: #CC3300;\">\r\n <h3 style=\"color: #CC3300;\"><span class=\"ez-toc-section\" id=\"For_Patients\"><\/span><i class=\"fas fa-users\"><\/i> For Patients<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>Advocate for options based on <strong>biological logic<\/strong> when standard protocols fail. The absence of a Phase 3 trial does not mean the absence of hope.<\/p>\r\n <\/div>\r\n \r\n <div class=\"info-box\">\r\n <h3><span class=\"ez-toc-section\" id=\"For_Medicine\"><\/span><i class=\"fas fa-stethoscope\"><\/i> For Medicine<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>Recognize that \"No Evidence\" often simply means <strong>\"No Commercial Incentive.\"<\/strong> We must find ways to validate promising therapies that fall outside the patent system.<\/p>\r\n <\/div>\r\n \r\n <div class=\"info-box\">\r\n <h3><span class=\"ez-toc-section\" id=\"For_Science\"><\/span><i class=\"fas fa-microscope\"><\/i> For Science<span class=\"ez-toc-section-end\"><\/span><\/h3>\r\n <p>Shift focus from suppressing symptoms (VEGF ablation) to <strong>restoring mitochondrial health<\/strong>. This is the future of regenerative ophthalmology.<\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <!-- Footer -->\r\n <footer style=\"margin-top: 80px; padding-top: 30px; border-top: 2px solid #E0E0E0; text-align: center; color: #666; font-size: 18px;\">\r\n <p><em>\"Absence of evidence is not evidence of absence.\"<\/em> \u2014 Carl Sagan<\/p>\r\n <p style=\"margin-top: 20px;\">This article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare provider before making any treatment decisions.<\/p>\r\n <\/footer>\r\n <\/article>\r\n<\/body>\r\n<\/html>\r\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>CLICK HERE TO DOWNLOAD PDF Absence of Evidence: SkQ1 (Visomitin) for AMD A Critical Examination Absence of Evidence: SkQ1 (Visomitin) for AMD “Absence of evidence is not evidence of absence.” \u2014 Carl Sagan The Treatment Gap in AMD Current standard of care for Age-Related Macular Degeneration (AMD) focuses exclusively on symptom management rather than addressing the underlying cause. This creates a significant gap in patient outcomes. Feature Standard of Care The Gap SkQ1 Potential Targets Root Cause No Mitochondrial dysfunction ignored Yes Treats Dry AMD No […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"h5ap_radio_sources":[],"cybocfi_hide_featured_image":"","footnotes":""},"categories":[52],"tags":[],"class_list":["post-15156","post","type-post","status-publish","format-standard","hentry","category-marketing-blogs"],"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":false,"author_link":"https:\/\/craighordlow.com\/author\/craig\/"},"_links":{"self":[{"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/posts\/15156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/comments?post=15156"}],"version-history":[{"count":8,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/posts\/15156\/revisions"}],"predecessor-version":[{"id":15202,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/posts\/15156\/revisions\/15202"}],"wp:attachment":[{"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/media?parent=15156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/categories?post=15156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/craighordlow.com\/index.php\/wp-json\/wp\/v2\/tags?post=15156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}